ZA200708591B - Pyrimidine derivatives for treatment of hyperproliferative disorders - Google Patents

Pyrimidine derivatives for treatment of hyperproliferative disorders

Info

Publication number
ZA200708591B
ZA200708591B ZA200708591A ZA200708591A ZA200708591B ZA 200708591 B ZA200708591 B ZA 200708591B ZA 200708591 A ZA200708591 A ZA 200708591A ZA 200708591 A ZA200708591 A ZA 200708591A ZA 200708591 B ZA200708591 B ZA 200708591B
Authority
ZA
South Africa
Prior art keywords
treatment
pyrimidine derivatives
hyperproliferative disorders
hyperproliferative
disorders
Prior art date
Application number
ZA200708591A
Other languages
English (en)
Inventor
Julie A Dixon
Nagarathnam Dhanapalan
Zhang Lei
Wang Chunguang
Yi Lin
Chen Yuanwei
Chen Jianqing
Brian R Bear
Brands Michael
Hillisch Alexander
Bierer Donald
Wang Ming
Fu Wenlang
Martin F Hentemann
Bullion Ann-Marie
Patel Manoj
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36624969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200708591(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ZA200708591B publication Critical patent/ZA200708591B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
ZA200708591A 2005-03-10 2007-10-09 Pyrimidine derivatives for treatment of hyperproliferative disorders ZA200708591B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66056105P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
ZA200708591B true ZA200708591B (en) 2009-01-28

Family

ID=36624969

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708591A ZA200708591B (en) 2005-03-10 2007-10-09 Pyrimidine derivatives for treatment of hyperproliferative disorders

Country Status (23)

Country Link
US (1) US20110098301A1 (xx)
EP (1) EP1858882A1 (xx)
JP (1) JP2008533042A (xx)
KR (1) KR20080004488A (xx)
CN (1) CN101151258A (xx)
AR (1) AR053554A1 (xx)
AU (1) AU2006223199A1 (xx)
BR (1) BRPI0609022A2 (xx)
CA (1) CA2601257A1 (xx)
CR (1) CR9347A (xx)
DO (1) DOP2006000061A (xx)
EA (1) EA200701930A1 (xx)
GT (1) GT200600105A (xx)
IL (1) IL185498A0 (xx)
MA (1) MA29377B1 (xx)
MX (1) MX2007010102A (xx)
NO (1) NO20074964L (xx)
PE (1) PE20061067A1 (xx)
TN (1) TNSN07322A1 (xx)
TW (1) TW200724537A (xx)
UY (1) UY29414A1 (xx)
WO (1) WO2006099231A1 (xx)
ZA (1) ZA200708591B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001477A4 (en) * 2006-03-20 2010-07-21 Bayer Healthcare Llc COMBINATION OF PACLITAXEL
CN101765591B (zh) * 2007-07-26 2013-11-27 诺华股份有限公司 用于治疗炎性或过敏性病症的嘧啶衍生物
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
CN103228274A (zh) 2010-10-01 2013-07-31 拜耳知识产权有限责任公司 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合
CN103270026A (zh) 2010-12-21 2013-08-28 诺瓦提斯公司 作为vps34抑制剂的联-杂芳基化合物
CN103492370B (zh) 2011-04-22 2016-10-26 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9638690B2 (en) 2014-11-07 2017-05-02 The University Of British Columbia Compounds and compositions for use as alkylating agent sensors and methods of use thereof
CA2975260A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2993173C (en) 2015-07-24 2023-10-03 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
TWI609028B (zh) 2016-05-06 2017-12-21 財團法人工業技術研究院 共聚物與含其之樹脂組合物、封裝膜及封裝結構
CN111518078B (zh) * 2020-05-30 2021-02-26 南方医科大学 一种含氨基吡啶的嘧啶类化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089480B2 (ja) * 1990-09-20 2000-09-18 ソニー株式会社 フリットシール装置
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
JP4948173B2 (ja) * 2003-10-10 2012-06-06 ニツポネツクス・インコーポレーテツド 過剰増殖性疾患治療用ピリミジン誘導体

Also Published As

Publication number Publication date
UY29414A1 (es) 2006-10-02
AU2006223199A1 (en) 2006-09-21
BRPI0609022A2 (pt) 2010-01-12
CA2601257A1 (en) 2006-09-21
AR053554A1 (es) 2007-05-09
IL185498A0 (en) 2008-01-06
TNSN07322A1 (en) 2008-12-31
EA200701930A1 (ru) 2008-02-28
CR9347A (es) 2007-12-17
KR20080004488A (ko) 2008-01-09
MA29377B1 (fr) 2008-04-01
MX2007010102A (es) 2007-10-12
DOP2006000061A (es) 2006-09-30
US20110098301A1 (en) 2011-04-28
EP1858882A1 (en) 2007-11-28
WO2006099231A1 (en) 2006-09-21
TW200724537A (en) 2007-07-01
CN101151258A (zh) 2008-03-26
GT200600105A (es) 2007-02-14
NO20074964L (no) 2007-12-06
PE20061067A1 (es) 2006-11-30
JP2008533042A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
IL185498A0 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
IL185052A0 (en) Treatment of bone disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
SI1907374T1 (sl) Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
IL187715A0 (en) Use of phenylsemicarbazones for seed treatment
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
PL1959957T3 (pl) Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości
GB0605715D0 (en) Treatment of laminitis
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL189524A0 (en) Imidazole compounds for the treatment of neurological disorders
EP1901770A4 (en) METHOD FOR TREATING GROWTH TROUBLESHOOTING
IL189853A0 (en) Treatment of neurodegenerative disorders
GB2432586B (en) Treatment of neurodegenerative disorders
IL188894A0 (en) Compounds for treatment of lipase-mediated diseases
GB0725077D0 (en) Antifolate com[ounds for the treatment of melanoma
ZA200800393B (en) Use of phenylsemicarbazones for seed treatment
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain